Mesalazine inhibits the β-catenin signalling pathway acting through the upregulation of μ-protocadherin gene in colo-rectal cancer cells

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 1, 2010, Pages 108-119

  Parenti, S ^a   Ferrarini, F ^a   Zini, R ^a   Montanari, M ^a   Losi, L ^a   Canovi, B ^b   Ferrari, S ^a   Grande, A ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b SOFAR Spa   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CADHERIN; MESALAZINE; MU PROTOCADHERIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LABORATORY TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

BETA CATENIN; CADHERINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESALAMINE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 71449124570     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04149.x     Document Type: Article

References (27)

1. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000 342 : 1960 1968.
2. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003 348 : 883 890. (Pubitemid 36297996)
3. Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol 2008 14 : 4434 4439.
4. Cheng Y, Desreumaux P. 5-Aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J Gastroenterol 2005 11 : 309 314.
5. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003 18 (Suppl. 2 10 4.
6. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005 201 : 1205 1215.
7. Reinacher-Schick A, Schoeneck A, Graeven U, Schwarte-Waldhoff I, Schmiegel W. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003 24 : 443 451.
8. Gasche C, Goel A, Natarajan L, Boland CR. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res 2005 65 : 3993 3997.
9. Chu EC, Chai J, Ahluwalia A, Tarnawski AS. Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?. Aliment Pharmacol Ther 2007 25 : 1443 1449.
10. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007 132 : 221 235.
11. Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 2006 27 : 2371 2382.
12. van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002 111 : 241 250.
13. Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol 2007 27 : 7551 7559.
14. Olmeda D, Castel S, Vilaro S, Cano A. Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol Biol Cell 2003 14 : 2844 2860.
15. Aoki K, Aoki M, Sugai M, et al. Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells. Oncogene 2007 26 : 3511 3520.
16. Dihlmann S, Von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005 113 : 515 524.
17. Manfredini R, Balestri R, Tagliafico E, et al. Antisense inhibition of c-fes proto-oncogene blocks PMA-induced macrophage differentiation in HL60 and in FDC-P1/MAC-11 cells. Blood 1997 89 : 135 145.
18. Grande A, Manfredini R, Pizzanelli M, et al. Presence of a functional vitamin D receptor does not correlate with vitamin D3 phenotypic effects in myeloid differentiation. Cell Death Differ 1997 4 : 497 505.
19. Gemelli C, Montanari M, Tenedini E, et al. Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell Death Differ 2006 13 : 1686 1696.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 25 : 402 408.
21. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001 154 : 369 387.
22. Hou R, Liu L, Anees S, Hiroyasu S, Sibinga NE. The Fat1 cadherin integrates vascular smooth muscle cell growth and migration signals. J Cell Biol 2006 173 : 417 429.
23. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005 65 : 3980 3985.
24. Moulton DE, Crandall W, Lakhani R, Lowe ME. Expression of a novel cadherin in the mouse and human intestine. Pediatr Res 2004 55 : 927 934.
25. Goldberg M, Peshkovsky C, Shifteh A, Al-Awqati Q. Mu-Protocadherin, a novel developmentally regulated protocadherin with mucin-like domains. J Biol Chem 2000 275 : 24622 24629.
26. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 2003 3 : 601 614.
27. Christofori G. New signals from the invasive front. Nature 2006 441 : 444 450.